by Raynovich Rod | Apr 27, 2016 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
Biotech Bear Market: XLV —A Large Cap Healthcare ETF Outperforms We have compared the performance of top mutual funds in the past and thought it would be interesting to see what happens in a bear market which began in September of 2015. Our last review was in...
by Raynovich Rod | Apr 4, 2016 | Biopharmaceuticals
Update 4/6/16 Biotech Rally Picks Up Momentum Today IBB up 4.5%,XBI up 5% Speculative stocks lead the way: BLUE up 10%, VRX up 16.6% ——–Risk on mode continues——— Healthcare Sector Leads the Market Lagging healthcare and biotech...
by Raynovich Rod | Mar 30, 2016 | 2025 Rayno Biopharmaceuticals Portfolio
Rayno Biopharmaceutical Portfolio Update- Biotechs with Upside Opportunity Caution No Rush to “Load Up” in a Bear Market Since Mid-January all of our previous portfolios were placed on hold and we recommended four new positions as long term holds. Here are...
by Raynovich Rod | Mar 9, 2016 | Biopharmaceuticals
Biotech Bear Market Rally is Fading but Traders Are Favored Long Term Concerns on Drug Pricing Remain The biotech sector is still lagging other sectors in 2016 down 20.93% with the IBB compared to the S&P 500 (SPY) down only 2.19%. The IBB rallied over the past...
by Raynovich Rod | Mar 2, 2016 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-2… Broad Tradable Rally Continues 12:30 PM EST XBI leads IBB today up 4.2% vs 2.9%. XBI at $54 is now up 9.55% over 5 days and well off Feb. 11 bottom of $44. This is a broad rally today with most biotech stocks up and the most speculative stocks are big...
by Raynovich Rod | Feb 22, 2016 | Biopharmaceuticals
2/23 After Close—Energy Rout Burns Biotech Stocks and NASDAQ The red screen dominated except few winners like ZIOPHARM Oncology (ZIOP) up 13.95% on a publication regarding gene editing. Another gene editing stock and recent IPO Editas Medicine (EDIT) was up...
by Raynovich Rod | Feb 16, 2016 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Rayno Large Cap Biopharmaceuticals…Part 2…A Stock pickers Market Time to Rebuild Your Portfolio: ABBV, BMY, GILD Below we have summarized selective metrics for large cap biopharmaceutical companies. We began the process of revising and rebalancing our...
by Raynovich Rod | Feb 10, 2016 | 2025 Rayno Biopharmaceuticals Portfolio, Macro
Have we reached a tradeable bottom in the biotech bear market? Today’s tape showed good volume but gains faded late in session. NASDAQ up 0.35% XLV up 0.88%-healthcare is the leading sector The biotech market bounced back early today in a broad rally...
by Raynovich Rod | Feb 3, 2016 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
2/5/16 …11:20 AM Biotechs Can’t Hold Gains …Drop Back Near 52 Week Lows Hit Wednesday IBB $261 XBI $48 Update-2 At Close 2/4/16…Nice Rally But Off Earlier Highs-Very Stock Specific A nice snap-back rally with a lot of green screen across the...
by Raynovich Rod | Feb 2, 2016 | 2025 Rayno Biopharmaceuticals Portfolio
Where is the Growth Potential in Large Cap Biopharmaceutical Companies? Caution: Risk Aversion Remains High Investing in biotech stocks ain’t getting easier. The sector is underperforming the market by 16% YTD, sentiment has been burned by concerns about drug...
